Article
19 Sep 2025
汉坤 • 观点 | 细胞与基因治疗领域又一利好：研究者发起的临床研究（IIT）管理办法正式落地
RANKINGS
This author falls within the Top 20% for their listed topics and industry categories. Based on Mondaq users readership, this author is ranked as VERY POPULAR in China
AUTHORS CONTENT
Article
19 Sep 2025
汉坤 • 观点 | 解读2024年版《赫尔辛基宣言》最新亮点 — 全球医学研究伦理准则系统性更新
Article
18 Sep 2025
China Released Draft Medical Device Law For Comments
Article
18 Sep 2025
China Pilots Lifting Restrictions On Foreign Investment In Stem Cell, Gene Therapy, And Genetic Diagnosis Sectors In Four Free Trade Zones
Article
18 Sep 2025
Key Takeaways on China's Pilot Plan for Segmented Production of Biological Products
Article
16 Sep 2025
2024年NewCo与药械License-in/out项目核心条款数据分析与对比
Article
16 Sep 2025
2024 Data Analytics: China Life Sciences NewCo & Licensing Terms
Article
16 Sep 2025
速评《美国优先投资政策备忘录》对中国生物医药行业的潜在影响
Article
16 Sep 2025
观点 | 中美关税博弈对医药行业的影响快评
Article
16 Sep 2025
Strengthening Oversight of Imported Drugs: Key Takeaways into New Regulations on Domestic Responsible Entities
Article
12 Sep 2025
解读人类遗传资源管理最新问答：人源细胞系、肿瘤异种移植模型（CDX/PDX）、CAR-T治疗材料监管问题
Article
12 Sep 2025
生命科学行业License-in/out合同争议要点分析（三）：不竞争条款
Article
12 Sep 2025
观点 | 生命科学行业License-in/out合同争议要点分析（四）：首付款是否可能退回？
Article
12 Sep 2025
Compliance Highlights And Strategies In High-Risk Clinical Research Landscape
Article
11 Sep 2025
Analysis Of China's New Draft Of Drug Regulatory Data Protection Rule: A New Perspective On Innovative Drug Transactions
Article
29 Aug 2025
Six Key Insights Into China Biotech's NewCo Model
Article
04 Apr 2025
揭秘中国创新药企NewCo模式实战中的"六脉神剑"
Article
02 Dec 2022
Overview Of China Drug Review Annual Report (2015-2021)
Article
25 Nov 2022
人遗相关法规之《科学技术部行政处罚实施办法（征求意见稿）》重点快评
Article
22 Nov 2022
Highlights On The New HGR-Related Administrative Penalty Rule
